The latest report by IMARC Group, titled "Bioabsorbable Stents Market Report by Biomaterial (Polymer-based Bioabsorbable Stents, Metal-based Bioabsorbable Stents), Absorption Rate (Slow-Absorption Stents, Fast-Absorption Stents), Application (Coronary Artery Disease, Peripheral Artery Disease), End User (Hospitals, Cardiac Centers), and Region 2025-2033," finds that the global bioabsorbable stents market size reached USD 438.0 Million in 2024. Bioabsorbable stents (BRS) are advanced medical tools coated with an antiproliferative drug or gene that dissolves to restore vessel patency. It regulates the blood flow at branch points and limits the amount of blood to areas of the vascular network while also maintaining the flow. In addition, it reduces vessel irritation and inflammation, improves lesion imaging with cardiac computed tomography (CT), and facilitates repeat treatments to the same site. As a result, BRS is widely utilized in hospitals and cardiac centers across the globe.
Global Bioabsorbable Stents Market Trends:
The market is primarily driven by the growing prevalence of cardiovascular diseases caused by physical inactivity and excessive tobacco and alcohol consumption. In addition, the increasing preference for minimally invasive (MI) procedures, as they offer less postoperative pain, fewer complications, shortened hospital stay, and faster recovery times, is contributing to the market growth. Apart from this, the leading market players are conducting research and development (R&D) activities to introduce SLENDER integrated delivery system (IDS), fixed-wire, and DIRECT RX bioabsorbable rapid-exchange drug-eluting stent (DES) systems to treat coronary artery disease. This, coupled with the increasing utilization of percutaneous coronary intervention (PCI) procedures for opening a blocked artery and carrying oxygen-rich blood through the body, is creating a positive market outlook across the globe. Looking forward, IMARC Group expects the market value to reach USD 786.5 Million by 2033, exhibiting a CAGR of 6.72% during the forecast period (2025-2033).
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Biomaterial, Absorption Rate, Application, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, Arterius Limited, B. Braun SE, Biotronik SE & Co. KG, Boston Scientific Corporation, Elixir Medical Corporation, Kyoto Medical Planning Co. Ltd., Lepu Medical Technology (Beijing) Co. Ltd., Meril Life Sciences Pvt. Ltd., Reva Medical LLC and Terumo Corporation |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N A
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800